<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821715</url>
  </required_header>
  <id_info>
    <org_study_id>THN102-201</org_study_id>
    <secondary_id>2015-005035-41</secondary_id>
    <nct_id>NCT02821715</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients</brief_title>
  <official_title>Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 study is a 8-site, double-blind, randomised, placebo-controlled, 3-way
      cross-over trial, involving 3 treatments with Modafinil 300 mg or the combination drug THN102
      (Modafinil/Flecainide 300 /3 mg, Modafinil/Flecainide 300 /27 mg).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 3 double blind periods (2-week) follow a stabilisation period for modafinil at 300 mg/day
      (open, 2-week) and are followed by a one-week washout period with the same modafinil dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epworth Sleepiness Scale (ESS)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
    <description>Range 0 to 24, low score indicates good outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily sleepiness assessment</measure>
    <time_frame>Daily pattern (during the 14 days of treatment period)</time_frame>
    <description>modified ESS, low score indicates good outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>14-item Fatigue Scale</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGI-C)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>14 days after the beginning of treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Narcolepsy</condition>
  <arm_group>
    <arm_group_label>Modafinil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 300/3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 300/27</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active comparator: Modafinil + placebo</intervention_name>
    <arm_group_label>Modafinil + placebo</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 300/3</intervention_name>
    <arm_group_label>THN102 300/3</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide 3 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 300/27</intervention_name>
    <arm_group_label>THN102 300/27</arm_group_label>
    <other_name>Modafinil 300 mg</other_name>
    <other_name>Flecainide 27 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:

          -  Patients with a diagnosis of narcolepsy type 1 (i.e. with cataplexy) or type 2
             (without cataplexy) according to the International Classification of Sleep Disorders
             (ICSD-3) criteria.

          -  Body mass index &gt;18 kg/m2 and &lt;35 kg/m2.

          -  Patients treated with modafinil at stable dosage for at least 2 months and still
             complaining of excessive daily somnolence (EDS) despite the treatment

          -  Epworth Sleepiness Scale (ESS) score should be ≥ 14/24 during the baseline period.

        Main exclusion Criteria:

          -  Patients with an untreated sleep apnea syndrome (respiratory disorder index &gt; 30/h) or
             who have any other cause of daytime sleepiness as assessed on patient history.

          -  Psychiatric and neurological disorders, other than narcolepsy/cataplexy, such as
             Parkinson's disease, Alzheimer's disease, Huntington's Chorea, multiple sclerosis,
             moderate or severe psychosis or dementia, bipolar illness, epilepsy, severe clinical
             anxiety or depression, Beck Depression Inventory ≥ 21 or with suicidal risk (if item &gt;
             0), or other problem that in the investigator's opinion would preclude the patient's
             participation and completion of this trial or comprise reliable representation of
             subjective symptoms.

          -  Contraindication to flecainide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Dauvilliers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Montpellier, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RespiSom</name>
      <address>
        <city>Erpent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lilles</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 26, 2020</submitted>
    <returned>June 9, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

